Enough is Enough': Sanders Demands Treasury Block Pfizer Tax Dodging Deal

[Benton]

(03-22-2016, 03:15 PM)Mike M (the other one) Wrote: They have been, but they got Viagra in the US extended to December 2020. Lyrica is December 2018.
So they are free to move now and lose their top seller and a top 5 right away.

Lipitor expired in 2012, so they've already felt the loss of that one.
Celebrex was going to expire in December of 2014, but they got an 18 month extension (June 2016).

Beats losing them now, if they were to leave prior to Dec 2020

That works out pretty well in their favor.

Really all their looking at losing is Viagra. And most likely they'll sue citing the previous US extension and tie it up in court for a couple years. So, at worse, they lose a year or two of the Viagra extension (you're welcome for the free pun), and they get to keep $35 billion. And if I remember right, Viagra sales come in somewhere under $1 billion, but they've ben declining.

So, at worst, they're up $33-34 billion even if they lose the Viagra patent and don't sell a single blue pill that year (which won't happen as some insurance companies still only cover name brand). At best, they're up $35-$38 billion with the back taxes and no drop off in Viagra sales.